Chemistry:Glycerol phenylbutyrate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Ravicti |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C33H38O6 |
| Molar mass | 530.661 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Glycerol phenylbutyrate, sold under the brand name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[2] It is an FDA-approved prescription drug in the US.[3] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013.[4]
Society and culture
Economics
Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[5]
References
- ↑ "Ravicti- glycerol phenylbutyrate liquid". 13 September 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=900e7dc0-9afe-4f50-80de-90567bb78519.
- ↑ "FDA approves new drug for the chronic management of some urea cycle disorders" (Press release). U.S. Food and Drug Administration. 1 February 2013. Archived from the original on 2013-03-07. Retrieved 2013-04-01.
- ↑ "FDA Approved Drug Products: Ravicti". Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=203284.
- ↑ "Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada". Journal of Law and the Biosciences 3 (1): 158–166. April 2016. doi:10.1093/jlb/lsv060. PMID 27774236.
- ↑ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". Genetic Engineering & Biotechnology News. 30 March 2015. http://www.genengnews.com/gen-news-highlights/horizon-pharma-to-acquire-hyperion-therapeutics-for-1-1b/81251089/.
 |  |
